Literature DB >> 19295478

Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats.

Toshiaki Iba1, Toshio Takayama.   

Abstract

Prophylactic use of anticoagulants during sepsis is strongly recommended for the prevention of venous thrombosis. Moreover, recent studies suggested the positive effects of anticoagulants to the inflammation. In this study, we planned to confirm the effects of heparins on protecting against endothelial damage in endotoxemia. In addition, we also examined the differences between unfractionated heparin (UFH) and enoxaparin. Wistar rats received 8.5 mg/kg (i.v.) LPS, followed by a bolus infusion of either 350 U/kg of UFH, 2.0 mg/kg of enoxaparin, or placebo. Microscopic observation of the mesenteric microcirculation and the measurement of the bleeding area after puncture with a microneedle were performed 3 h later (n = 6 in each group). In another series, blood samples were taken 3 h after the LPS injection, and blood cell counts, coagulation markers, and organ damage markers were measured (n = 6 in each). As a result, the leukocyte adherence to the endothelium was significantly reduced in both the UFH and enoxaparin groups, and thus, endothelial damage was attenuated in these groups. The bleeding area was markedly expanded in the UFH group compared with the other groups (P < 0.01 each). The decrease in white blood cells and platelet count was significantly suppressed in the enoxaparin group compared with the UFH group (P < 0.05 each). The fibrinogen level was maintained at significantly better levels, and the elevation of alanine aminotransferase was significantly suppressed in enoxaparin group (P < 0.05 each). In conclusion, both UFH and enoxaparin protect against endothelial damage by preventing leukocyte adhesion. However, UFH significantly increases the bleeding area, whereas enoxaparin does not increase bleeding, and thus, it can reduce organ damages in the endotoxemic rat.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295478     DOI: 10.1097/SHK.0b013e3181a2e279

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo.

Authors:  Shengjie Li; Joshua A Marks; Rachel Eisenstadt; Kenichiro Kumasaka; Davoud Samadi; Victoria E Johnson; Daniel N Holena; Steven R Allen; Kevin D Browne; Douglas H Smith; Jose L Pascual
Journal:  J Trauma Acute Care Surg       Date:  2015-07       Impact factor: 3.313

2.  Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.

Authors:  J Marc Simard; E Francois Aldrich; David Schreibman; Robert F James; Adam Polifka; Narlin Beaty
Journal:  J Neurosurg       Date:  2013-09-13       Impact factor: 5.115

3.  Enoxaparin sodium prevents intestinal microcirculatory dysfunction in endotoxemic rats.

Authors:  Yu-Chang Yeh; Ming-Jiuh Wang; Chih-Peng Lin; Shou-Zen Fan; Jui-Chang Tsai; Wei-Zen Sun; Wen-Je Ko
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

4.  Dose-Dependent Hemodynamic, Biochemical, and Tissue Oxygen Effects of OC99 following Severe Oxygen Debt Produced by Hemorrhagic Shock in Dogs.

Authors:  William W Muir; Carlos L Del Rio; Yukie Ueyama; Bradley L Youngblood; Robert S George; Carl W Rausch; Billy S H Lau; Robert L Hamlin
Journal:  Crit Care Res Pract       Date:  2014-10-27

5.  Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction.

Authors:  Toshiaki Iba; Naoyuki Hashiguchi; Isao Nagaoka; Yoko Tabe; Katsuhiko Kadota; Koichi Sato
Journal:  Intensive Care Med Exp       Date:  2015-12-29

Review 6.  Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock.

Authors:  Daniel De Backer; Diego Orbegozo Cortes; Katia Donadello; Jean-Louis Vincent
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.